Advanced robotics enable successful lung biopsies

Together we completed over 20,000 cases.1 When using MONARCH, physicians achieved over 15% improvement in overall diagnostic yield2 compared to traditional bronchoscopy. This means fewer patients had to ‘wait and see.’

1.7

average number of biopsies a patient needs to get diagnosis3

33.5%

5-year survival rate if lung cancer has spread to regional lymph nodes4

61.2%

survival rate if lung cancer is diagnosed and treated early5

Clinical Studies

Robotic-assisted Bronchoscopy and Cone-beam CT (CBCT)​. A Retrospective Series.

Learn from a physician’s recent experience in the use of CBCT with the MONARCH Platform, where 100% tool-in-lesion confirmation was achieved.6

AABIP 2022 Poster: Demographic and Lesion Characteristics of first 443 subjects in TARGET.

Learn about the interim analysis of a large multicenter prospective real-world observation study. RAB with MONARCH Platform had 97.5% navigation success with median lesion size reported as 18.5 mm. Compared to a prior prospective study of the MONARCH Platform, nodule size appears smaller and procedure time is shorter in this cohort.7

Gateway Customer Portal

Our customers have access to data and insights through our secure web-portal to support their MONARCH experience. Improve efficiency with access to platform usage data, order information, training, and marketing support materials.

Control gives you freedom

Control gives you freedom

The MONARCH Platform reaches deep into the periphery of the lung. Once at the target, easily adjust the bronchoscope tip with precise, sub-millimeter movements using a handheld style controller. The robotic bronchoscope provides stability, maintaining the scope tip position during biopsy.

Adaptive navigation with Sensor Fusion Technology

Adaptive navigation with Sensor Fusion Technology

CT-to-Body Divergence can affect all bronchoscopy procedures.  The MONARCH Platform uses Sensor Fusion Technology to adapt for this divergence by combining multiple sensing modalities and adapting to intraoperative changes in real time.  By leveraging Computer Vision, EM technology, and Robotic Data, MONARCH enables physicians to identify small airways and recalibrate to find your target. 
 

Vision in the periphery

Vision in the periphery

The MONARCH Platform is designed to provide vision throughout the procedure. Limited vision, or no vision, forces you to rely on other technology to approximate location and trajectory of your tools, which can make biopsies more challenging. 

With an integrated camera, you now have the added benefit of being able to directly visualize the biopsy field and instruments. 

The MONARCH Platform is also compatible with the leading advanced intraoperative imaging systems, inclusive of fixed gantry or mobile interventional CBCT and mobile CT imaging systems. 

Disclaimers

Bronchoscopy Indications for Use: The MONARCH Platform and its accessories are intended to provide bronchoscopic visualization of and access to patient airways for diagnostic and therapeutic procedures.

Bronchoscopy Important Safety Information: Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).

 

References

1. Procedural volume count recorded in SalesForce.com as of 10/6/22

2.“Comparison of DY reported in Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study. Folch, et. al. J Thorac Oncol. 2019 Mar;14(3):445-458. doi: 10.1016/j.jtho.2018.11.013. Epub 2018 Nov 23. PMID: 30476574 and in internal data 103-000810-00 Rev A reporting on initial findings of Multi-Center Retrospective Chart Review”.

3. “Biopsy frequency and complications among lung cancer patients in the United States”. Zhang Y, et al. Cancer Manag. 2020 Aug 17;9(4):LMT40. doi: 10.2217/lmt-2020-0022. PMID: 33318758; PMCID: PMC7729592.

4. "Cancer Stat Facts: Lung and Bronchus Cancer." National Cancer Institute, Accessed Sept 12, 2022, https://seer.cancer.gov/statfacts/html/lungb.html

5."Cancer Stat Facts: Lung and Bronchus Cancer." National Cancer Institute, Accessed Sept 12, 2022, https://seer.cancer.gov/statfacts/html/lungb.html

6.Cumbo-Nacheli, Gustavo MD; Velagapudi, Ravi K. MD; Enter, Mark RN; Egan, John P. III MD; Conci, Diego MD. Robotic-assisted Bronchoscopy and Cone-beam CT: A Retrospective Series. Journal of Bronchology & Interventional Pulmonology: August 2, 2022 - Volume - Issue - 10.1097/LBR.0000000000000860
doi: 10.1097/LBR.0000000000000860

7. Septimiu Murgu, MD1 ; Daniel Sterman, MD2 ; Kazuhiro Yasufuku, MD3 ; Alexander Chen, MD4 ; Balaji Laxmanan, MD5 ; Jaime Connelly, MS6 ; Mengqi Xiao, MS6 ; Samaan Rafeq, MD5 ; Gerard Silvestri, MD7, Demographic and Lesion Characteristics in the First 443 Subjects Enrolled in a Multicenter Observational Real-World Robotic Bronchoscopy Study: Interim Results From TARGET

 

MBRPRO-000846-01 Rev B © 2022 Ethicon, Inc. All rights reserved.